AU3596500A - Formulation of 5-ht agonists with cox-2 inhibitors - Google Patents

Formulation of 5-ht agonists with cox-2 inhibitors

Info

Publication number
AU3596500A
AU3596500A AU35965/00A AU3596500A AU3596500A AU 3596500 A AU3596500 A AU 3596500A AU 35965/00 A AU35965/00 A AU 35965/00A AU 3596500 A AU3596500 A AU 3596500A AU 3596500 A AU3596500 A AU 3596500A
Authority
AU
Australia
Prior art keywords
cox
agonists
inhibitors
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35965/00A
Inventor
John R. Plachetka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pozen Inc
Original Assignee
Pozen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pozen Inc filed Critical Pozen Inc
Publication of AU3596500A publication Critical patent/AU3596500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU35965/00A 1999-02-19 2000-02-16 Formulation of 5-ht agonists with cox-2 inhibitors Abandoned AU3596500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25327899A 1999-02-19 1999-02-19
US09253278 1999-02-19
PCT/US2000/003897 WO2000048583A2 (en) 1999-02-19 2000-02-16 Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine

Publications (1)

Publication Number Publication Date
AU3596500A true AU3596500A (en) 2000-09-04

Family

ID=22959600

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35965/00A Abandoned AU3596500A (en) 1999-02-19 2000-02-16 Formulation of 5-ht agonists with cox-2 inhibitors

Country Status (2)

Country Link
AU (1) AU3596500A (en)
WO (1) WO2000048583A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
ES2234324T3 (en) 1998-11-02 2005-06-16 MERCK & CO., INC. COMBINATIONS OF A 5HT1B / 1D AGONIST AND A COX-2 SELECTIVE INHIBITOR FOR THE TREATMENT OF MIGRAINE.
SA99191255B1 (en) 1998-11-30 2006-11-25 جي دي سيرل اند كو celecoxib compounds
WO2001000229A1 (en) * 1999-06-24 2001-01-04 Pharmacia Corporation Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation
GB9929039D0 (en) * 1999-12-08 2000-02-02 Glaxo Group Ltd Medicaments
GB0002336D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
WO2002017896A2 (en) * 2000-08-29 2002-03-07 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
BR0312795A (en) * 2002-07-19 2005-05-10 Ranbaxy Lab Ltd Pharmaceutical presentation of sumatriptan, process for its preparation and method for treating migraine
AU2003303631B2 (en) 2002-12-26 2008-05-29 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Multilayer Dosage Forms Containing NSAIDs and Triptans
EP2266585B1 (en) 2003-05-07 2013-06-26 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
RU2008152196A (en) * 2006-06-15 2010-07-20 Новартис АГ (CH) COMPOSITIONS, INCLUDING TAGASEROD IN SEPARATELY OR IN COMBINATION WITH A PROTON PUMP INHIBITOR, FOR TREATMENT OR PREVENTION OF GASTRONOMAL INJURIES
EP3000462A1 (en) 2008-04-28 2016-03-30 Zogenix, Inc. Novel formulations for treatment of migraine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2135884B (en) * 1983-03-09 1986-09-17 Sandoz Ltd Analgesic preparations containing tizanidine and paracetamol
DE19542281C2 (en) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Use of Epinastin for the treatment of migraines
SI9720035B (en) * 1996-04-12 2009-10-31 Searle & Co Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
ES2234324T3 (en) * 1998-11-02 2005-06-16 MERCK & CO., INC. COMBINATIONS OF A 5HT1B / 1D AGONIST AND A COX-2 SELECTIVE INHIBITOR FOR THE TREATMENT OF MIGRAINE.

Also Published As

Publication number Publication date
WO2000048583A2 (en) 2000-08-24
WO2000048583A3 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
AU2001232036A1 (en) Pyrimidine derivatives as selective inhibitors of cox-2
AU6934600A (en) Cd40 ligand and cd40 agonist compositions and methods of use
AU8030598A (en) Indole compounds as cox-2 inhibitors
AU2619800A (en) Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
AU2722797A (en) Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
AU4604200A (en) Laser-ultrasonic measurement of wall thickness
AU2563900A (en) Quinoline derivatives as tyrosine kinase inhibitors
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
AU3596500A (en) Formulation of 5-ht agonists with cox-2 inhibitors
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2003301216A1 (en) Novel use of liver x receptor agonists
AU2575201A (en) Use of hsp27 as an anti-inflammatory agent
AU4782499A (en) Substituted imidazo(1,2A)azines as selective inhibitors of COX-2
AU6482200A (en) Use of amh and/or amh agonists and/or amh antagonists for long-term control of female fertility
AU2203801A (en) Formulations of adenosine a1 agonists
AU2002238103A1 (en) Use of beta-lactamase inhibitors as neuroprotectants
AU2203601A (en) Formulations of adenosine a1 agonists
AU7126900A (en) Enzyme inhibitors
AU4501199A (en) 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
AU9512298A (en) Beta3-adrenoreceptor agonists, agonist compositions and methods of using
AU6589200A (en) Extended release formulation of etodolac
AU2002214038A1 (en) Inhibitors of transglutaminases
AU2575399A (en) Oxazole derivatives as serotonin-1a receptor agonists
AU5179800A (en) Mycolactone and related compounds, compositions and methods of use
AU2001259626A1 (en) Indole derivatives and their use as 15-lipoxygenase inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase